{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:20Z","timestamp":1791849620453,"version":"4.3.4"},"posted":{"date-parts":[[2023,10,23]]},"group-title":"In Review","reference-count":20,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T00:00:00Z","timestamp":1698019200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2023,9,23]]},"abstract":"<title>Abstract<\/title>\n        <p>The approach to patients with high-risk smoldering multiple myeloma (SMM) varies among clinicians; while some advocate early intervention, others reserve treatment at progression to multiple myeloma (MM). We aimed to describe the myeloma-defining events (MDEs) and clinical presentations leading to MM diagnosis among SMM patients seen at our institution. We included 406 patients diagnosed with SMM between 2013-2022, seen at Mayo Clinic, Rochester, MN. The 2018 Mayo 20\/2\/20 criteria were used for risk stratification. Median follow-up was 3.9 years. Among high-risk patients who did not receive treatment in the SMM phase (n=71), 51 progressed by last follow-up; the MDEs included: bone lesions(37%), anemia(35%), hypercalcemia(8%), and renal failure(6%); 24% met MM criteria based on marrow plasmacytosis (\u226560%) and\/or free light chain ratio (&gt;100); 45% had clinically significant MDEs (hypercalcemia, renal insufficiency, and\/or bone lesions). MM diagnosis was made based on surveillance labs\/imaging(45%), testing obtained due to provider suspicion for progression(14%), bone pain(20%), and hospitalization\/ED presentations due to MM complications\/symptoms(4%). The presentation was undocumented in 14%. A high proportion (45%) of patients with high-risk SMM on active surveillance develop end-organ damage at progression. About a quarter of patients who progress to MM are not diagnosed based on routine interval surveillance testing.<\/p>","DOI":"10.21203\/rs.3.rs-3378634\/v1","type":"posted-content","created":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T23:39:17Z","timestamp":1698104357000},"source":"Crossref","is-referenced-by-count":1,"title":["Mode of Progression in Smoldering Multiple Myeloma: A study of 406 patients"],"prefix":"10.21203","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5862-1833","authenticated-orcid":false,"given":"S","family":"Rajkumar","sequence":"first","affiliation":[{"name":"Mayo Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9195-1589","authenticated-orcid":false,"given":"Nadine","family":"Abdallah","sequence":"additional","affiliation":[{"name":"Mayo clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjun","family":"Lakshman","sequence":"additional","affiliation":[{"name":"Mayo clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji","family":"Kumar","sequence":"additional","affiliation":[{"name":"Mayo clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5335-9533","authenticated-orcid":false,"given":"Joselle","family":"Cook","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9014-9658","authenticated-orcid":false,"given":"Moritz","family":"Binder","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4342-364X","authenticated-orcid":false,"given":"Prashant","family":"Kapoor","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8780-9512","authenticated-orcid":false,"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3853-5196","authenticated-orcid":false,"given":"Morie","family":"Gertz","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Lacy","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"HAYMAN","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3214-0203","authenticated-orcid":false,"given":"Francis","family":"Buadi","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7477-3004","authenticated-orcid":false,"given":"David","family":"Dingli","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1556-6416","authenticated-orcid":false,"given":"Yi","family":"Lin","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8573-9434","authenticated-orcid":false,"given":"Taxiarchis","family":"Kourelis","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahma","family":"Warsame","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1523-7388","authenticated-orcid":false,"given":"P. Leif","family":"Bergsagel","sequence":"additional","affiliation":[{"name":"Mayo Clinic in Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"issue":"24","key":"ref1","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1056\/NEJM198006123022405","article-title":"Smoldering Multiple Myeloma","volume":"302","author":"Kyle RA","year":"1980","unstructured":"Kyle RA, Greipp PR. Smoldering Multiple Myeloma. New England Journal of Medicine. 1980;302(24):1347\u20139.","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"ref2","doi-asserted-by":"crossref","first-page":"e538-48","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar SV","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538-48.","journal-title":"Lancet Oncol"},{"issue":"10","key":"ref3","doi-asserted-by":"crossref","first-page":"e486","DOI":"10.1038\/bcj.2016.100","article-title":"Prevalence, incidence and survival of smoldering multiple myeloma in the United States","volume":"6","author":"Ravindran A","year":"2016","unstructured":"Ravindran A, Bartley AC, Holton SJ, Gonsalves WI, Kapoor P, Siddiqui MA, et al. Prevalence, incidence and survival of smoldering multiple myeloma in the United States. Blood Cancer J. 2016;6(10):e486.","journal-title":"Blood Cancer J"},{"issue":"2","key":"ref4","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/s41591-022-02183-6","article-title":"Prevalence of smoldering multiple myeloma based on nationwide screening","volume":"29","author":"Thorsteinsd\u00f3ttir S","year":"2023","unstructured":"Thorsteinsd\u00f3ttir S, G\u00edslason GK, Aspelund T, R\u00f6gnvaldsson S, \u00d3skarsson J\u00de, Sigur\u00f0ard\u00f3ttir G\u00c1, et al. Prevalence of smoldering multiple myeloma based on nationwide screening. Nature Medicine. 2023;29(2):467\u201372.","journal-title":"Nature Medicine"},{"issue":"7","key":"ref5","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","article-title":"New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells","volume":"110","author":"Perez-Persona E","year":"2007","unstructured":"Perez-Persona E, Vidriales MB, Mateo G, Garcia-Sanz R, Mateos MV, de Coca AG, et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood. 2007;110(7):2586\u201392.","journal-title":"Blood"},{"issue":"6","key":"ref6","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41408-018-0077-4","article-title":"Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria","volume":"8","author":"Lakshman A","year":"2018","unstructured":"Lakshman A, Rajkumar SV, Buadi FK, Binder M, Gertz MA, Lacy MQ, et al. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer J. 2018;8(6):59.","journal-title":"Blood Cancer J"},{"issue":"10","key":"ref7","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41408-020-00366-3","article-title":"International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)","volume":"10","author":"Mateos MV","year":"2020","unstructured":"Mateos MV, Kumar S, Dimopoulos MA, Gonzalez-Calle V, Kastritis E, Hajek R, et al. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer J. 2020;10(10):102.","journal-title":"Blood Cancer J"},{"issue":"11","key":"ref8","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1200\/JCO.19.01740","article-title":"Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma","volume":"38","author":"Lonial S","year":"2020","unstructured":"Lonial S, Jacobus S, Fonseca R, Weiss M, Kumar S, Orlowski RZ, et al. Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma. J Clin Oncol. 2020;38(11):1126\u201337.","journal-title":"J Clin Oncol"},{"issue":"5","key":"ref9","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1300439","article-title":"Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma","volume":"369","author":"Mateos MV","year":"2013","unstructured":"Mateos MV, Hernandez MT, Giraldo P, de la Rubia J, de Arriba F, Lopez Corral L, et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med. 2013;369(5):438\u201347.","journal-title":"N Engl J Med"},{"issue":"7","key":"ref10","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/s41375-020-0718-z","article-title":"Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)","volume":"34","author":"Landgren CO","year":"2020","unstructured":"Landgren CO, Chari A, Cohen YC, Spencer A, Voorhees P, Estell JA, et al. Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS). Leukemia. 2020;34(7):1840\u201352.","journal-title":"Leukemia"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1182\/blood-2019-125204","article-title":"Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd","volume":"134","author":"Mateos M-V","year":"2019","unstructured":"Mateos M-V, Martinez-Lopez J, Rodriguez Otero P, Gonzalez-Calle V, Gonzalez MS, Oriol A, et al. Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd. Blood. 2019;134:781.","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/blood-2020-136148","article-title":"Treatment of High Risk (HR) Smoldering Multiple Myeloma (SMM) with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed By Lenalidomide Maintenance (-R): A Phase 2 Clinical and Correlative Study","volume":"136","author":"Kazandjian D","year":"2020","unstructured":"Kazandjian D, Hill E, Morrison C, Dew A, Korde N, Mailankody S, et al. Treatment of High Risk (HR) Smoldering Multiple Myeloma (SMM) with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed By Lenalidomide Maintenance (-R): A Phase 2 Clinical and Correlative Study. Blood. 2020;136:43\u20135.","journal-title":"Blood"},{"issue":"Supplement 1","key":"ref13","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1182\/blood-2018-154","article-title":"Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma","volume":"132","author":"Liu C-j","year":"2018","unstructured":"Liu C-j, Ghobrial IM, Bustoros M, Reyes K, Hornburg K, Badros AZ, et al. Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma. Blood. 2018;132(Supplement 1):154-.","journal-title":"Blood"},{"issue":"Supplement_1","key":"ref14","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1182\/blood-2019-123205","article-title":"A Multicenter Phase II Single Arm Trial of Isatuximab in Patients with High Risk Smoldering Multiple Myeloma (HRSMM)","volume":"134","author":"Manasanch EE","year":"2019","unstructured":"Manasanch EE, Jagannath S, Lee HC, Patel KK, Graham C, Kaufman GP, et al. A Multicenter Phase II Single Arm Trial of Isatuximab in Patients with High Risk Smoldering Multiple Myeloma (HRSMM). Blood. 2019;134(Supplement_1):3116-.","journal-title":"Blood"},{"issue":"8","key":"ref15","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S1470-2045(16)30124-3","article-title":"Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial","volume":"17","author":"Mateos MV","year":"2016","unstructured":"Mateos MV, Hernandez MT, Giraldo P, de la Rubia J, de Arriba F, Corral LL, et al. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial. Lancet Oncol. 2016;17(8):1127\u201336.","journal-title":"Lancet Oncol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ejca.2022.07.030","article-title":"Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: A randomized, open-label study","volume":"174","author":"Mateos MV","year":"2022","unstructured":"Mateos MV, Hern\u00e1ndez MT, Salvador C, Rubia J, de Arriba F, L\u00f3pez-Corral L, et al. Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: A randomized, open-label study. Eur J Cancer. 2022;174:243\u201350.","journal-title":"Eur J Cancer"},{"issue":"9","key":"ref17","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41408-022-00719-0","article-title":"Smoldering multiple myeloma current treatment algorithms","volume":"12","author":"Rajkumar SV","year":"2022","unstructured":"Rajkumar SV, Kumar S, Lonial S, Mateos MV. Smoldering multiple myeloma current treatment algorithms. Blood Cancer J. 2022;12(9):129.","journal-title":"Blood Cancer J"},{"issue":"11","key":"ref18","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1080\/10428194.2021.1951723","article-title":"Should high risk smoldering myeloma be treated outside a clinical trial: NO","volume":"62","author":"Gertz MA","year":"2021","unstructured":"Gertz MA, Vaxman I. Should high risk smoldering myeloma be treated outside a clinical trial: NO. Leuk Lymphoma. 2021;62(11):2565\u20137.","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"ref19","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1053\/j.seminoncol.2019.03.001","article-title":"State of the science in smoldering myeloma: Should we be treating in the clinic?","volume":"46","author":"Hill E","year":"2019","unstructured":"Hill E, Dew A, Kazandjian D. State of the science in smoldering myeloma: Should we be treating in the clinic? Semin Oncol. 2019;46(2):112\u201320.","journal-title":"Semin Oncol"},{"issue":"10","key":"ref20","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41408-020-00366-3","article-title":"International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)","volume":"10","author":"Mateos MV","year":"2020","unstructured":"Mateos MV, Kumar S, Dimopoulos MA, Gonz\u00e1lez-Calle V, Kastritis E, Hajek R, et al. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer J. 2020;10(10):102.","journal-title":"Blood Cancer J"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-3378634\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-3378634\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T08:15:02Z","timestamp":1705652102000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-3378634\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,23]]},"references-count":20,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-3378634\/v1","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1038\/s41408-024-00980-5","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2023,10,23]]},"subtype":"preprint"}}